0001209191-18-004661.txt : 20180119
0001209191-18-004661.hdr.sgml : 20180119
20180119210030
ACCESSION NUMBER: 0001209191-18-004661
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180117
FILED AS OF DATE: 20180119
DATE AS OF CHANGE: 20180119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Azelby Robert
CENTRAL INDEX KEY: 0001656998
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36781
FILM NUMBER: 18538572
MAIL ADDRESS:
STREET 1: 307 WESTLAKE AVE. NORTH, STE 300
CITY: SEATTLE
STATE: WA
ZIP: 98109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Juno Therapeutics, Inc.
CENTRAL INDEX KEY: 0001594864
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463656275
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 2065821600
MAIL ADDRESS:
STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200
CITY: SEATTLE
STATE: WA
ZIP: 98109
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-01-17
0
0001594864
Juno Therapeutics, Inc.
JUNO
0001656998
Azelby Robert
C/O 400 DEXTER AVENUE NORTH
SUITE 1200
SEATTLE
WA
98109
0
1
0
0
EVP & Chief Commercial Officer
Common Stock
2018-01-17
4
M
0
2498
25.29
A
73330
D
Common Stock
2018-01-17
4
M
0
26633
20.76
A
99963
D
Common Stock
2018-01-17
4
S
0
21141
68.10
D
78822
D
Common Stock
2018-01-17
4
S
0
7990
69.95
D
70832
D
Stock Option (Right to Buy)
25.29
2018-01-17
4
M
0
2498
0.00
D
2026-11-07
Common Stock
2498
30836
D
Stock Option (Right to Buy)
20.76
2018-01-17
4
M
0
26633
0.00
D
2027-02-06
Common Stock
26633
101208
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017.
1/48th of the shares subject to the option vested and became exercisable on December 8, 2016 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter.
1/48th of the shares subject to the option vested and became exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter.
/s/ Zachary D. Hale, attorney-in-fact
2018-01-19